Amadeus Capital Partners’ Post

The surgical challenge of organ transplantation was overcome in the 1960s, immunological in the 1980s, but not until 2021 was there another breakthrough moment. This is when the pioneering technology developed by OrganOx broke the association of quality and time with donated organs. Normothermic perfusion helps to extend the window of time an organ remains viable for transplant when outside the human body. Rather than simply 'placing it on ice', organs are kept at optimal condition by perfusing with oxygenated blood. Watch the clip below, or for the full story of OrganOx follow the link 👇 https://bit.ly/3SacLsL #organox #breakthrough #techbio #vc

On this #GratitudeFriday, we’re celebrating the work of TransMedics, Inc. The organization was founded to address the growing need for healthier organs for transplantation. They're focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs. TransMedics' Organ Care System is a transformative technology designed to better preserve, assess, and maintain donor organs, potentially reducing the number of unused organs by addressing the key limitations of current preservation methods. To learn more about TransMedics, visit https://lnkd.in/eve3riy8

🗞️𝐀𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐇𝐚𝐧𝐝𝐞𝐥𝐬𝐛𝐥𝐚𝐭𝐭, 𝐨𝐧𝐞 𝐨𝐟 𝐆𝐞𝐫𝐦𝐚𝐧𝐲'𝐬 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐧𝐞𝐰𝐬𝐩𝐚𝐩𝐞𝐫𝐬!🗞️ In the article, titled "𝘈𝘭𝘭𝘰𝘨𝘦𝘯𝘦𝘵𝘪𝘤𝘴: 𝘉𝘪𝘰𝘵𝘦𝘤𝘩 𝘊𝘰𝘮𝘱𝘢𝘯𝘺 𝘧𝘳𝘰𝘮 𝘏𝘢𝘯𝘯𝘰𝘷𝘦𝘳 𝘈𝘪𝘮𝘴 𝘵𝘰 𝘔𝘢𝘬𝘦 𝘋𝘰𝘯𝘰𝘳 𝘖𝘳𝘨𝘢𝘯𝘴 𝘐𝘯𝘷𝘪𝘴𝘪𝘣𝘭𝘦", our groundbreaking approach to organ transplantation is highlighted. Instead of relying on lifelong immunosuppression, our innovative technology creates immunological invisibility for donor organs, offering a promising new direction in transplantation medicine. 🔗 Read the full article here: https://lnkd.in/dejnwMEa The article highlights our innovative work in making organ transplantation safer and more effective. We're excited to continue advancing our mission and achieving new milestones.🎉 A big thank you to Handelsblatt for covering our story. Stay tuned for more updates as we continue to innovate and make a difference in the field of organ transplantation!🙏🏼 #Allogenetics #OrganTransplant #InvisibleOrgans #HealthcareInnovation #StartUpLife

💊Developing a first-of-its-kind nanomedicine to improve kidney transplant success and patient outcomes! In their just-launched €900K Eurostars NANOMED-KT project, Mercurna and project partner, Karolinska Institutet aim to develop a new mRNA-based therapy to prevent delayed graft function. This is a form of acute kidney injury occuring within the first week of kidney transplantation, affecting 20-60% of transplant recipients. Jenny van Asbeck-van der Wijst, Mercurna CEO, commented, “The Eurostars funding provides us with the resources to enhance our platform technology, expand our research capabilities, and foster collaborations with leading institutions like the Karolinska Institutet. Beyond the immediate scope of the NANOMED-KT project, this support helps us make significant strides towards developing life-changing treatments for inflammatory diseases, thereby improving the quality of life for patients worldwide.” We are proud to have supported Mercurna towards their Eurostars award! 🔗 Read the full article here: https://lnkd.in/esKRaqiU #Mercurna #NanoMedicine #Eurostars #getfundingmakeimpact

🌟 HOPE for the Week: Outcomes of redo-liver transplantation using hypothermic oxygenated machine perfusion (HOPE): a preliminary analysis of a multicentre cohort study (REDO-HOPE) was presented last week at TTS. The study aimed at investigating outcomes of redo-LT performed using grafts treated by HOPE. By improving preservation and allowing prolonged preservation time, HOPE was shown to improve outcomes of redo-LT. Take a look at the full abstract here: https://ow.ly/4Mb250TzEH6 #HopeForTheWeek #LiverTransplant #TTS

🔥 ASCO 2024 Plenary: Prof Dr Jeroen Dekervel (UZ Leuven) and Prof Dr Florian Lordick (University of Leipzig) discuss the ESOPEC trial, comparing FLOT perioperative chemotherapy with neoadjuvant chemoradiotherapy for adenocarcinoma of the oesophagus or oesophagogastric junction. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GICancer #OncologyInnovation

Organ scarcity poses a demanding challenge on a nation where more than 100,000 people wait for the possibility of a donor organ transplant. This morning, Newsweek asked Paragonix founder and CEO, Dr. Lisa Anderson, how optimizing today's technologies can make an impact. "While the state of transplantation is not without challenges, we can address many of them with the technology we have today," Dr. Anderson shared. "We owe it to patients waiting for a second chance to build on our progress and achieve even more through ongoing research, innovation, and collaboration across the industry." Read the full article on Newsweek: https://lnkd.in/eMmt_9_B https://lnkd.in/eAM3Eg_6

LyGenesis has introduced an innovative experimental therapy designed to grow miniature livers within patients' lymph nodes, offering a groundbreaking approach to medical treatment. Known as LYG-LIV-001, this therapy involves transplanting hepatocytes from donated livers into the recipient's lymph nodes, where they are anticipated to mature into fully functional liver tissue. Primarily focusing on end-stage liver disease (ESLD), this treatment holds promise in mitigating the acute shortage of organ donors, potentially leading to significant advancements in patient care and saving numerous lives. Although the trial's outcome remains uncertain, LyGenesis envisions broader applications for this technology, such as cultivating tissues for kidneys, thymus, and pancreas, paving the way for transformative developments in the field of regenerative medicine. #Doctors #Liver #Transplant #Trial

**🔬 Revolutionizing Organ Procurement with PerfusionomiX** At PerfusionomiX, we are committed to advancing the future of organ procurement and transplantation. By leveraging cutting-edge perfusion technology, we aim to improve organ preservation, reduce ischemic damage, and extend the viability of organs outside the body. 💡 Our approach is designed to enhance the quality of donated organs, increasing successful transplants and ultimately saving more lives. From heart and lung preservation to liver and kidney support, we’re dedicated to transforming the way the medical community approaches organ procurement. 🚀 Together with our partners, we’re leading the charge to ensure more patients receive the life-saving transplants they need. At PerfusionomiX, innovation isn't just our mission—it's our promise to the future of healthcare. #PerfusionomiX #OrganProcurement #TransplantInnovation #MedicalAdvancement #HealthcareTech #PerfusionTechnology #OrganTransplant #OrganRecovery #DonateLife #TransplantSolutions #NRP

Today, we highlight the newsletter by one of our members, Organización Nacional de Trasplantes (ONT), with an editorial by Beatriz Domínguez-Gil. 💡In the latest edition of the Newsletter Transplant, readers can compare organ donation and transplantation activities between countries globally and by transplant type, in 2022 versus 2021 and 2020. 📈The data from 2020 highlights the profound impact of the COVID-19 pandemic, while 2021 and 2022 showed a progressive recovery, with a global increase in transplant activities of 13% and 9% respectively. The newsletter also features data from the Eurocet platform by BRAVEST member Centro Nazionale Trapianti, which includes information on the donation, procurement, processing, distribution and clinical use of tissues and cells. 🔗Access the full newsletter here: https://lnkd.in/drscG4Gp